Ofra Novoplansky

441 citations
12 papers · 217 indexed · h-index 8
Topics
Peptidase Inhibition and Analysis (4 papers)Head and Neck Cancer Studies (3 papers)Lung Cancer Treatments and Mutations (3 papers)

In The Last Decade

Ofra Novoplansky

12 papers receiving 214 citations

Peers

Ofra Novoplansky
Comparison fields: 5 of 46
  • Molecular Biology 132
  • Oncology 93
  • Pulmonary and Respiratory Medicine 31
  • Cancer Research 31
  • Immunology 27
Replace Irati Garmendia with:
Irati Garmendia Spain
Xian-Zi Yang China
Dale W. Lewis United States
Guo-Rung You Taiwan
Carolina Carneiro Soares Macedo Brazil
Sanjana Bukkapatnam United States
Nathan Benaich United Kingdom
Tong-Xin Xie United States
Christina Möller‐Koop Germany
Francesc Muyas United Kingdom
Ofra Novoplansky relative to Irati Garmendia Spain Irati Garmendia's profile →
Citations per field
00.5×
Irati Garmendia · 1×
Citations per year

Countries citing papers authored by Ofra Novoplansky

Since Specialization
Citations

This map shows the geographic impact of Ofra Novoplansky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ofra Novoplansky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ofra Novoplansky more than expected).

Fields of papers citing papers by Ofra Novoplansky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ofra Novoplansky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ofra Novoplansky. The network helps show where Ofra Novoplansky may publish in the future.

Co-authorship network of co-authors of Ofra Novoplansky

This figure shows the co-authorship network connecting the top 25 collaborators of Ofra Novoplansky. A scholar is included among the top collaborators of Ofra Novoplansky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ofra Novoplansky. Ofra Novoplansky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
#WorkIndexed citations
1 1
2 19
3 9
4 5
5 15
6 5
7 30
8 1
9 30
10 47
11 24
12 31

About Ofra Novoplansky

Ofra Novoplansky is a scholar working on Otorhinolaryngology, Oncology and Hepatology, having authored 12 papers that have together received 217 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (4 papers), Head and Neck Cancer Studies (3 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Otorhinolaryngology (21 citations), Oncology (93 citations) and Cancer Research (31 citations). Ofra Novoplansky has collaborated with scholars based in Israel, United States and Germany. Frequent co-authors include Moshe Elkabets, Sankar Jagadeeshan, Ksenia M. Yegodayev, Manu Prasad, Jonathan Zorea, Limor Cohen, Ben‐Zion Joshua, Michael Brandeis, Ron R. Kopito and Elham Alsahafi. Their work appears in journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026